Cencora, Inc. (COR) AI Stock Summary

Snapshot

Cencora is a massive pharmaceutical distributor that moves huge volumes with thin margins. FY 2025 revenue was $321.33B, up 9.3%, but gross margin is only 3.2%. The company is highly profitable on the bottom line with $1.55B in net income and generates strong free cash flow of $3.21B annually. It holds $4.39B in cash against $10.75B in debt, a comfortable position for a business of this scale.

What's Happening Right Now

• Wed 1st Jul '26 · Earnings: Cencora scheduled its third-quarter fiscal 2026 earnings release for August 5, 2026.
• Tue 2nd Jun '26 · Partnership: Cencora agreed to support the U.S. distribution of Kite's FDA-approved CAR T-cell therapies.
• Wed 27th May '26 · Management: Eva Boratto was appointed Executive Vice President and Chief Financial Officer, effective June 29, 2026.
• Thu 21st May '26 · Capital Allocation: Cencora raised its fiscal 2026 earnings forecast and approved a new $2 billion stock buyback program.

Bottom Line

Cencora is a cash-generating machine operating in a low-margin but essential industry. The recent earnings miss looked worse than the business reality, leading management to raise guidance and authorize a large buyback that signals confidence. With the stock trading in the middle of its 52-week range at a modest valuation, the financial picture is healthy and the capital allocation is shareholder-friendly.